Genetic architecture of complex traits predisposing to nephropathy: hypertension

Age-dependent association of the polymorphisms in the mitochondria-shaping gene, OPA1, with blood pressure and hypertension in Korean population

BACKGROUND

Essential hypertension is associated with mitochondrial dysfunction. Because mitochondrial dynamics; mitochondrial morphological changes are closely linked with various mitochondrial functions, we aimed to examine whether the genetic variation of the mitochondria-shaping genes influenced the susceptibility to blood pressure (BP) and hypertension.

METHODS

The quantitative BP trait analysis and hypertension case-control analysis for the total 52 single-nucleotide polymorphisms (SNPs) in the five major mitochondria-shaping genes were performed in the Korean Association Resource (KARE) study cohort (8,512 subjects).

RESULTS

In the total subjects of the KARE study cohort, there were no statistically significant associations of the SNPs in the five mitochondria-shaping genes with BP or hypertension after adjusting for multiple tests. However, the age group analysis in the 40s, 50s, and 60s age subgroups revealed that 15 SNPs out of 26 SNPs genotyped in the OPA1 gene were significantly associated with BP and/or hypertension in the 60s age subgroup and their association P values satisfied the Bonferroni-corrected significance level (P < 0.00625). Noticeably, nine SNPs were consistently associated with all the three traits; systolic BP (SBP), diastolic BP (DBP), and hypertension. In silico lookup of the associated SNPs in the Southern German population did not reveal associations with BP traits.

CONCLUSIONS

Our results indicate that genetic variation of the mitochondrial fusion-regulating gene, OPA1, might be associated with BP and hypertension in an age-dependent and population-specific manner in the Korean study cohort, and suggest that altered mitochondrial dynamics, especially involved in the mitochondrial fusion event, may play an important role in the pathogenesis of hypertension.

Strategies to improve detection of hypertension genes

Multiple factors contribute to the development of hypertension, including genetic factors and environmental exposures. Various pathophysiological mechanisms are at play in the pathogenesis of hypertension and this pathogenesis, by necessity, exhibits substantial variation at the level of the individual, as it depends on the relative contribution of inherited genes and individual lifetime environmental exposures. Over time, long-term compensatory mechanisms, including responses to either chronic hypertension or to therapeutic intervention, can only obscure the initiating mechanisms of disease. Acute compensating mechanisms can also mask initiating gene effects during or after an intervention, so that early phenotype assessments during the intervention may be more likely to detect the genetic initiators. Compensatory mechanisms, working over days, weeks or even years, will likely be variably effective in minimizing the expected blood pressure rise, making it difficult to detect genetic initiating mechanisms in cross-sectional, 'steady state', or 'in balance' studies. If the lifetime risk of hypertension indeed approaches 90%, the power to identify genetic factors can only decrease with duration of disease and treatment, and prediction of hypertension becomes of vanishing significance. With multiple factors at play, we cannot expect that all causes are mutually exclusive, but it is reasonable to assume that one of these mechanisms is predominant in the initiation of the disease in any one individual. Given the heterogeneity of essential hypertension argued above, it becomes evident that the chance of identifying genetic factors that contribute to disease development will be greatest if study subjects at highest genetic predisposition are observed during age ranges when heritability is at a maximum, using the correct phenotypes, measured in the correct tissues, during the correct time window. Genes found to be significant in such studies should be densely typed in clinical trials and large population studies to assess public health and clinical applications of the findings.